Search research articles
Contact Us
Filters
Showing results (141-150 of 196) with videos related to
Page
of 20
Sort By:
European Urology Open Science
|
July 11, 2022
The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy
David D'Andrea, Shahrokh F Shariat, Francesco Soria, et al.
Targeted Oncology
|
August 6, 2024
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project
Alessandro Rizzo, Fernando Sabino Marques Monteiro, Yüksel Ürün, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2023
Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study
Gazanfer Belge, Cansu Dumlupinar, Tim Nestler, et al.
European Urology Oncology
|
June 21, 2024
Clinical Validation of the Intermediate-risk Non-muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group Collaboration
Francesco Soria, Matteo Rosazza, Simone Livoti, et al.
BJU International
|
January 11, 2025
Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results
Pietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 16, 2022
Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets
Florian Kocher, Alberto Puccini, Gerold Untergasser, et al.
Clinical Genitourinary Cancer
|
December 13, 2024
Real-world Evidence for Enfortumab Vedotin in Patients with Metastatic Urothelial Cancer: An Austrian Multicentre Study
Dora Niedersuess-Beke, Karl Mayrhofer, Johanna Krauter, et al.
International Journal of Cancer
|
October 22, 2025
Enfortumab vedotin plus pembrolizumab in treatment-naïve metastatic urothelial carcinoma patients: An Austrian real-world analysis
Dora Niedersuess-Beke, Karl Mayrhofer, Johanna Krauter, et al.
Urologic Oncology
|
September 20, 2025
The influence of immunocompromised status on recurrence and progression free survival among nonmuscle invasive bladder cancers (NMIBCs) undergoing transurethral resection of bladder tumor (TURBT) and adjuvant intravesical bacillus Calmette Guerin (BCG): Analysis of USA insurance claim data
Francesco Del Giudice, Valerio Santarelli, Jan Łaszkiewicz, et al.
Clinical and Experimental Medicine
|
November 2, 2023
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study
Matteo Santoni, Francesco Massari, Hideki Takeshita, et al.
Page
of 20
Search research articles
Search
Showing results (141-150 of 196) with videos related to
Sort By:
Page
of 20
European Urology Open Science
|
July 11, 2022
The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy
David D'Andrea, Shahrokh F Shariat, Francesco Soria, et al.
Targeted Oncology
|
August 6, 2024
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project
Alessandro Rizzo, Fernando Sabino Marques Monteiro, Yüksel Ürün, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2023
Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study
Gazanfer Belge, Cansu Dumlupinar, Tim Nestler, et al.
European Urology Oncology
|
June 21, 2024
Clinical Validation of the Intermediate-risk Non-muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group Collaboration
Francesco Soria, Matteo Rosazza, Simone Livoti, et al.
BJU International
|
January 11, 2025
Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results
Pietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 16, 2022
Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets
Florian Kocher, Alberto Puccini, Gerold Untergasser, et al.
Clinical Genitourinary Cancer
|
December 13, 2024
Real-world Evidence for Enfortumab Vedotin in Patients with Metastatic Urothelial Cancer: An Austrian Multicentre Study
Dora Niedersuess-Beke, Karl Mayrhofer, Johanna Krauter, et al.
International Journal of Cancer
|
October 22, 2025
Enfortumab vedotin plus pembrolizumab in treatment-naïve metastatic urothelial carcinoma patients: An Austrian real-world analysis
Dora Niedersuess-Beke, Karl Mayrhofer, Johanna Krauter, et al.
Urologic Oncology
|
September 20, 2025
The influence of immunocompromised status on recurrence and progression free survival among nonmuscle invasive bladder cancers (NMIBCs) undergoing transurethral resection of bladder tumor (TURBT) and adjuvant intravesical bacillus Calmette Guerin (BCG): Analysis of USA insurance claim data
Francesco Del Giudice, Valerio Santarelli, Jan Łaszkiewicz, et al.
Clinical and Experimental Medicine
|
November 2, 2023
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study
Matteo Santoni, Francesco Massari, Hideki Takeshita, et al.
Page
of 20